Orgenesis

Cell & Gene Therapy

Health Tech & Life Sciences
Public on NASDAQ on Mar, 2018

Company Overview

Snapshot

Founded in January 2008, Orgenesis operates with 11–50 employees. The company has raised a total of $18.2 million across 5 funding rounds. Orgenesis became public on NASDAQ in March 2018.

Business overview

Orgenesis is a global biotech company specializing in cell and gene therapy. It leverages a unique Cell & Gene Therapy Biotech Platform to deliver life-changing treatments at the Point of Care (POCare), aiming to reduce costs and increase patient access. The platform integrates POCare Therapeutics, customized POCare Technologies for closed processing, and a collaborative global POCare Network. Orgenesis focuses on developing efficient, scalable, and affordable pathways for cell and gene therapies, serving the healthcare and life sciences industries, including laboratories, providers, pharmaceutical, and biotechnology sectors.

Strategic signal

In March 2025, Orgenesis Inc. announced the acquisition of certain Neurocords LLC assets, strategically strengthening its regenerative medicine portfolio with spinal cord injury therapies. This move signals Orgenesis's commitment to expanding its therapeutic pipeline and market reach within the advanced medical treatments sector, indicating a proactive growth strategy to investors.

Company Intelligence Q&A

What was a significant recent strategic acquisition by Orgenesis?
In March 2025, Orgenesis Inc. acquired certain assets from Neurocords LLC, enhancing its regenerative medicine portfolio with therapies for spinal cord injuries.
When did Orgenesis become a publicly traded company?
Orgenesis became public on NASDAQ in March 2018.
What was a key partnership announced by Orgenesis in 2023?
In May 2023, Orgenesis announced a collaboration agreement with SCTbio to expand POCare sites in the Czech Republic and enhance capabilities for lentivirus vector production.
What was a notable financial event for Orgenesis in November 2023?
In November 2023, Orgenesis Inc. announced the pricing of a $1.1 million registered direct offering.
What recognition did Orgenesis receive in November 2023?
In November 2023, Orgenesis was ranked as the 171st fastest-growing company in North America on the 2023 Deloitte Technology Fast 500™.

External links